Should I Buy GTBP? GTBP 2026 Analysis

Should You Buy GT Biopharma Inc (GTBP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.540

1 Day change

8.46%

52 Week Range

3.850

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: price action and momentum are decisively bearish and there are no proprietary buy signals to override that.
Despite positive FDA/news catalysts, the stock is still selling off (regular market -5.13%, post-market -3.93%), suggesting near-term demand is weak.
Best call based on the provided data: avoid new entries now (sell/avoid) until momentum turns and the stock reclaims key resistance levels (around 0.596+).

Technical Analysis

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Trend/momentum: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating persistent downtrend.
MACD: Histogram at -0.0229 and negatively expanding -> bearish momentum is strengthening, not stabilizing.
RSI(6): 21.884 indicates heavily oversold conditions (even if labeled “neutral” in the feed), but oversold alone is not a buy signal while MACD/MA trend remain bearish.
Key levels:
- Near-term resistance/pivot: 0.596 (pivot), then 0.726 (R1).
- Support: 0.467 (S1); if that fails, 0.387 (S2).
Pattern-based forward read (from similar candlesticks): expected drift lower (-0.41% next day, -0.45% next week, -2.32% next month), reinforcing a weak near-term setup.

Positive Catalysts

- FDA approval to initiate Phase 1 trial for GTB-5550 (solid tumors) is a clear event-driven catalyst that can improve sentiment and visibility.
- Cash runway update: company expects ~ $9M cash as of Jan 31, 2026, guiding funding through Q4 2026 (reduces immediate financing pressure).
- Clear upcoming clinical milestones: Phase 1 expected to start mid-2026; dose-escalation design and targeted tumor types provide a defined narrative.
- Analyst remains constructive: Roth maintains a Buy rating (even after cutting target).

Neutral/Negative Catalysts

- Price action is actively bearish (down in regular session and further down post-market), implying the market is not rewarding the catalyst yet.
- No proprietary Intellectia buy signals today (neither AI Stock Picker nor SwingMax), reducing confidence in a near-term tradable bottom.
- Development-stage risk profile: no meaningful revenue base and outcomes depend on future clinical data (timing risk until mid-2026/1Q26 readouts for other programs).
- Key technical risk: a break below ~0.467 support opens room toward ~0.387.

Financial Performance

Latest provided quarter: 2025/Q3.
Revenue: 0 (no operating revenue base).
Profitability: Net loss worsened to -$3.258M (down -4.49% YoY).
EPS: -0.83 (down -45.75% YoY), indicating accelerating per-share losses.
Overall: financial trend reflects continued cash burn typical of pre-revenue biotech; the main “growth” driver is pipeline progress rather than reported sales.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Most recent analyst update (2025-11-17, Roth Capital): Maintained Buy, but price target cut to $8 from $11 (downward revision).
What Wall Street is effectively saying:
- Pros: Pipeline advancement (TriKE programs), upcoming trial/data milestones, and defined catalysts.
- Cons: Limited cash historically noted (though later news suggests improved runway), no revenue, ongoing losses, and execution risk until clinical data arrives.
Net read: Analysts are still optimistic on long-term upside, but the target cut signals reduced confidence/greater risk discounting in the near-to-medium term.

1 Analyst Rating

Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.496

Low

Averages

High

Current: 0.496

Low

Averages

High

Roth Capital

Buy

downgrade

$11 -> $8

AI Analysis

2025-11-17

Reason

Roth Capital

Price Target

$11 -> $8

AI Analysis

2025-11-17

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on GT Biopharma to $8 from $11 and keeps a Buy rating on the shares. GT Biopharma closed Q3 with $2.6M in cash, sufficient to fund operations into 1Q26, the analyst tells investors in a research note. The company is advancing a Phase 1 trial of second-generation TriKE GTB-3650 in relapsed/refractory CD33+ hematologic malignancies, with initial data expected in 1Q26, and has resumed preclinical development of GTB-5550 for B7H3+ solid tumors, targeting an IND submission by YE25/1Q26.

GTBP Should I Buy

GTBP Should I Buy

Should You Buy GT Biopharma Inc (GTBP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch